ICB International

What ICB International does

ICB International (Innovative California Biosciences International, Inc., operating as ICBI/ICBII) is a privately held, clinical-stage biotechnology company founded in 2008 by Dr. Ram Bhatt and headquartered in La Jolla, California. The company has developed the SMART Molecules (Specific Molecular Architecture for Recognition and Therapy) platform — proprietary heavy-chain-only antibody mimics of approximately 46 KDa molecular weight engineered to cross the blood-brain barrier and selectively bind pathological proteins in the central nervous system. The platform supports both diagnostic applications (radiolabeled SMART Molecules used with PET/SPECT imaging) and disease-modifying therapeutics, with lead candidates targeting α-synuclein for Parkinson's disease and Multiple System Atrophy (α-Syn-SM) and amyloid-beta for Alzheimer's disease (Aβ-SM), plus pipeline extensions into oncology and age-related macular degeneration.

The core technical differentiation lies in brain uptake of up to 15% versus approximately 0.1% for conventional monoclonal antibodies, an eight-day serum half-life enabling weekly dosing, and a modular architecture supporting up to four binding sites per molecule for multi-target engagement. Preclinical validation in transgenic mouse models has demonstrated up to 66% reduction in aggregated amyloid-beta and α-synuclein with low-dose weekly injections and survival extension in Alzheimer's transgenic mice. The intellectual property portfolio comprises seven approved US and European patents covering BBB-permeable peptide compositions, with multiple divisional and continuation applications pending, and third-party validation has been provided by Dr. Eliezer Masliah at UCSD.

Revenue generation is structured around technology licensing to pharmaceutical companies, with secondary optionality from future proprietary drug commercialization. ICBII has reported ongoing licensing discussions with three unnamed international pharmaceutical companies and is preparing for Phase 1 clinical trials while conducting a capital raise. Historical funding has come primarily from three Michael J. Fox Foundation grants (2013, 2015, 2016), supporting research into α-synuclein picobodies and SMART Molecules for Parkinson's disease. The company filed an Orphan Drug Designation application with FDA in 2017 for α-Syn-SM in Multiple System Atrophy.

Name

ICB International

Legal name

Innovative California Biosciences International, Inc.

Website

https://icbii.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

ICB International is a clinical-stage biotech developing SMART Molecules — proprietary antibody mimics that cross the blood-brain barrier to diagnose and treat Alzheimer's, Parkinson's, and other CNS disorders. The La Jolla-based company licenses its platform to pharmaceutical partners while preparing for Phase 1 trials.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / CNS Drug Delivery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Blood-brain barrier platform
• Antibody mimics
• Neurodegenerative therapeutics
• CNS drug delivery
• Biopharmaceutical drug development

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Technology Licensing: Licensing the SMART Molecules technology platform to pharmaceutical companies for drug development. The company has ongoing discussions with three international pharmaceutical companies interested in employing the technology for their products.
2. Clinical Development and Drug Sales: Development of proprietary therapeutics through clinical trials with potential for future commercial sales of disease-modifying drugs for Alzheimer's, Parkinson's, and other CNS disorders.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ICB International develops a proprietary SMART Molecule (Specific Molecular Architecture for Recognition and Therapy) drug-delivery platform consisting of ~46 KDa heavy-chain-only antibody mimics that cross the blood-brain barrier (BBB) to selectively bind pathological proteins in the central nervous system. The platform supports both diagnostic (radiolabeled PET imaging) and disease-modifying therapeutic applications for neurodegenerative disorders (Alzheimer's, Parkinson's, Multiple System Atrophy) with pipeline extensions into oncology and age-related macular degeneration. The company licenses the technology to pharmaceutical companies and advances its own proprietary candidates toward Phase 1 clinical trials.

Product overview

ICB International's core offering is the SMART Molecule Technology Platform (Specific Molecular Architecture for Recognition and Therapy), a proprietary drug development technology comprising small (~46 KDa) heavy-chain-only antibody mimics that efficiently cross the blood-brain barrier (BBB) and selectively bind to pathological proteins. The platform powers multiple products: α-Synuclein-SM (α-Syn-SM) for Parkinson's disease and Multiple System Atrophy diagnosis/therapy; Aβ-SM for Alzheimer's disease; radiolabeled SMART Molecules as PET/SPECT imaging tracers for early in vivo diagnosis; and pipeline candidates for oncology and age-related macular degeneration. One molecule can carry up to four binding sites, enabling multi-targeting. The company is in preclinical/clinical stage, advancing toward Phase 1 human trials.

Differentiator

Problem solved

Functional benefit

Products and services

• SMART Molecule Technology Platform A proprietary, modular drug development and delivery platform comprising antibody mimics (~46 KDa, heavy-chain only) designed to cross the blood-brain barrier and selectively target pathological CNS proteins, enabling both diagnosis and disease-modifying therapy for neurodegenerative disorders and cancers. Offered to pharmaceutical companies via licensing and supports the company's proprietary drug pipeline.
• α-Synuclein-SMART Molecule (α-Syn-SM) A SMART Molecule therapeutic/diagnostic candidate targeting α-synuclein for Parkinson's disease and Multiple System Atrophy (MSA); administered intravenously and demonstrated up to 66% reduction of aggregated α-synuclein in animal models with dose-dependent therapeutic effect; Orphan Drug Designation application filed for the MSA indication.
• Aβ-SMART Molecule (Aβ-SM) A SMART Molecule therapeutic/diagnostic candidate targeting amyloid-beta (Aβ) plaques for the diagnosis and treatment of Alzheimer's disease; demonstrated BBB permeability, binding to soluble Aβ monomers and plaques, and reduced amyloid burden in transgenic mouse models (up to 66% reduction with once-weekly low-dose injections over 8–12 weeks).
• Radiolabeled SMART Molecules for PET/SPECT Imaging Diagnostic imaging agents based on radiolabeled SMART Molecules used as PET/SPECT tracers for in vivo detection and quantification of pathological proteins in the brain, enabling early diagnosis and progression monitoring of Alzheimer's, Parkinson's, and other neurodegenerative diseases.
• SMART Molecules for Oncology Pipeline extension of the SMART Molecule platform applied to multiple oncology indications (brain, breast, colorectal, lung, prostate, and ovarian cancers), leveraging the platform's tissue-penetrating capability to deliver targeted therapeutics to tumors.
• SMART Molecules for Age-Related Macular Degeneration (AMD) Pipeline extension of the SMART Molecule platform to age-related and diabetes-related macular degeneration, utilizing the platform's tissue-barrier-penetrating capability for targeted delivery to ocular tissues.

Quantifiable outcome

• Up to 15% brain uptake vs 0.1% for conventional monoclonal antibodies
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Dr. David Vera, UCSDcoreStrategic or Co-development Partner · 1 December 2018Collaboration with Dr. David Vera, Professor of Radiology at UCSD and world-renowned authority in design and synthesis of targeted diagnostic agents. Dr. Vera developed the first FDA-approved Tc-99m-galactosyl-neoglycoalbumin. This collaboration helps ICBII develop radiolabeled SMART Molecules for imaging Alzheimer's, Parkinson's and MSA animals.
• UC IrvinecoreStrategic or Co-development Partner · 1 January 2015Collaboration with UC Irvine to study pharmacodynamics of SMART Molecules. Launched in 2015 to advance understanding of SM technology and its effects.
• Dr. Eliezer Masliah, University of California San DiegocoreStrategic or Co-development Partner · 1 January 2014Third-party validation of ICBI's blood-brain barrier permeability and target specificity. Dr. Masliah confirmed that amyloid-beta-SM and alpha-synuclein-SM traffic and breach the BBB and reach their targets, while conventional monoclonal antibodies do not. Experiments conducted in alpha-synuclein transgenic mice proved ability to penetrate BBB and specifically bind to Lewy body-like deposits and alpha-syn aggregates.
• CIMS (Centre D'imagerie Moleculaire de Shebrooke), CanadacoreStrategic or Co-development Partner · 1 January 2014Collaboration with CIMS for radiochemistry for labeling of alpha-synuclein picobody, followed by determination of biodistribution and pharmacokinetic studies. The collaboration was established upon receiving the MJFF grant to study pharmacology of alpha-synuclein-SM in 72 mice at the Center of Molecular Imaging, Canada.
• Three International Pharmaceutical CompaniesminorStrategic or Co-development PartnerOngoing discussions with three international pharmaceutical companies interested in employing ICBI's SMART Molecules technology for their products. No specific company names disclosed.
• Dr. Serge Muyldermans, Vrije Universiteit BrusselminorOthersDr. Muyldermans, world's expert in single-domain antibodies, joined ICBI's scientific advisory team in 2016 to provide expertise on single-domain antibody technology.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Denali Therapeutics: Clinical-stage biotech developing engineered protein therapeutics (including antibody-based) engineered to cross the BBB for neurodegenerative diseases such as Parkinson's and Alzheimer's. Direct technology and indication overlap with ICBI's SMART Molecule platform.
• Prothena Corporation: Biotech developing antibody-based therapeutics against misfolded proteins including alpha-synuclein (Parkinson's) and amyloid-beta (Alzheimer's). Direct target and modality overlap with ICBI's α-Syn-SM and Aβ-SM programs.

Emerging players

• Voyager Therapeutics: Gene therapy company developing AAV-based delivery platforms to cross the BBB for CNS disorders including Parkinson's. Comparable as a CNS delivery-platform specialist pursuing similar patient populations.
• Passage Bio: Clinical-stage gene therapy company focused on CNS disorders with delivery approaches designed to address the BBB challenge. Comparable as a CNS delivery-platform developer targeting neurodegenerative indications.
• AC Immune SA: Clinical-stage biotech developing antibody- and vaccine-based therapeutics for neurodegenerative diseases including Alzheimer's (anti-amyloid and anti-tau programs). Overlapping modality and indication focus with ICBI.
• Cassava Sciences: Clinical-stage biotech developing small-molecule therapeutics for Alzheimer's disease. Comparable as a CNS-focused company pursuing disease-modifying approaches in overlapping indications.
• Alzheon Inc. Clinical-stage biotech developing disease-modifying therapies for Alzheimer's disease, with focus on amyloid-targeting agents. Comparable as an indication-aligned but molecule-modality-different peer.

Broad incumbents

• Biogen: Large CNS-focused biopharma with marketed Alzheimer's therapy Leqembi (lecanemab) and a broad neuroscience pipeline. Represents the strategic acquirer/partner profile for ICBI's BBB platform assets.
• Eli Lilly: Large pharmaceutical company with major CNS investments including Kisunla (donanemab) for Alzheimer's and Parkinson's programs. Comparable as an established CNS franchise player that could be a licensing partner or competitor.
• Roche (Genentech): Large pharmaceutical company with extensive neuroscience investments including gantenerumab and other anti-amyloid programs for Alzheimer's. Comparable as a strategic CNS Big Pharma partner and competing platform developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ICBII
• Facebookfacebook.com/821792664557581
• LinkedInlinkedin.com/company/icb-international-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICB International